These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37010772)

  • 1. Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor.
    van Lint JA; Jessurun NT; Tas SW; Vonkeman HE; van Doorn MBA; Hoentjen F; Nurmohamed MT; van Puijenbroek EP; van den Bemt BJF
    BioDrugs; 2023 Jul; 37(4):541-550. PubMed ID: 37010772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases.
    van Lint JA; Jessurun NT; Hebing RCF; Hoentjen F; Tas SW; Vonkeman HE; van Doorn MBA; Sobels A; Spuls PI; van Puijenbroek EP; Nurmohamed MT; van den Bemt BJF
    Drug Saf; 2020 Sep; 43(9):917-925. PubMed ID: 32451974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-mediated inflammatory disease patients' preferences in adverse drug reaction information regarding biologics.
    Kosse LJ; Weits G; Vonkeman HE; Spuls PI; Van Den Bemt BJF; Tas SW; Hoentjen F; Nurmohamed MT; Van Doorn MBA; Van Puijenbroek EP; Jessurun NT
    Expert Opin Drug Saf; 2020 Aug; 19(8):1049-1054. PubMed ID: 32524887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapy.
    Thomas PWA; Römkens TEH; West RL; Russel MGVM; Jansen JM; van Lint JA; Jessurun NT; Hoentjen F
    United European Gastroenterol J; 2021 Oct; 9(8):919-928. PubMed ID: 34077634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases.
    Gosselt HR; van Lint JA; Kosse LJ; Spuls PI; Vonkeman HE; Tas SW; Hoentjen F; Nurmohamed MT; van den Bemt BJF; van Doorn MBA; Jessurun NT
    Expert Opin Drug Saf; 2023; 22(6):501-507. PubMed ID: 36794307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The importance of patient perspective in drug surveillance systems].
    Gäwert L; Hierse F; Zink A; Strangfeld A
    Z Rheumatol; 2010 Nov; 69(9):795-802. PubMed ID: 21063828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study.
    Roest LH; Kosse LJ; van Lint JA; Gosselt HR; Scholl JHG; van Puijenbroek E; Vonkeman HE; Tas SW; Nurmohamed MT; van den Bemt BJF; Jessurun NT
    Expert Opin Drug Saf; 2023 Mar; 22(3):203-211. PubMed ID: 36036179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stakeholders' perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases.
    Kosse LJ; Jessurun NT; Vonkeman HE; Tas SW; Nurmohamed MT; Hoentjen F; van Doorn MBA; van Puijenbroek EP; van den Bemt BJF; de Vries M
    Expert Opin Drug Saf; 2020 Nov; 19(11):1521-1528. PubMed ID: 32730115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals.
    van Lint JA; Jessurun NT; Tas SW; van den Bemt BJF; Nurmohamed MT; van Doorn MBA; Spuls PI; van Tubergen AM; Ten Klooster PM; van Puijenbroek EP; Hoentjen F; Vonkeman HE
    J Rheumatol; 2021 Sep; 48(9):1388-1394. PubMed ID: 33993115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
    Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
    Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes.
    Kosse LJ; Weits G; Vonkeman HE; Tas SW; Hoentjen F; Van Doorn MB; Spuls PI; D'Haens GR; Nurmohamed MT; van Puijenbroek EP; Van Den Bemt BJ; Jessurun NT
    Expert Opin Drug Saf; 2021 Dec; 20(12):1565-1572. PubMed ID: 34348543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The burden of adverse drug reactions reported by patients in the Dutch ADR monitor: a proof of concept.
    Quik JM; Gosselt HR; van Lint JA; Kosse LJ; Ten Klooster PM; Vonkeman HE; van den Bemt BJF; Jessurun NT
    Expert Opin Drug Saf; 2024 Jul; ():. PubMed ID: 39049766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions.
    Abasolo L; Leon L; Rodriguez-Rodriguez L; Tobias A; Rosales Z; Maria Leal J; Castaño V; Vadillo C; Macarron P; Fontsere O; Jover JA
    Semin Arthritis Rheum; 2015 Apr; 44(5):506-513. PubMed ID: 25532946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital.
    Jose J; Rao PG
    Pharmacol Res; 2006 Sep; 54(3):226-33. PubMed ID: 16781163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting.
    de Camargo MC; Barros BCA; Fulone I; Silva MT; Silveira MSDN; de Camargo IA; Barberato-Filho S; Del Fiol FS; Lopes LC
    Front Pharmacol; 2019; 10():965. PubMed ID: 31572173
    [No Abstract]   [Full Text] [Related]  

  • 16. Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Machado-Alba JE; Ruiz AF; Machado-Duque ME
    Rev Panam Salud Publica; 2014 Dec; 36(6):396-401. PubMed ID: 25711751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is improvement of fatigue in rheumatoid arthritis a proper effect of biologics?
    Ines M; Aicha BT; Leila R; Ali M; Thouraya G; Rawdha T; Olfa S; Leila A
    Rom J Intern Med; 2021 Mar; 59(1):58-65. PubMed ID: 33010144
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of a Framework Structuring Themes in the Course of Adverse Drug Reactions from a Patient's Perspective.
    van Lint JA; Sonnenberg M; Vonkeman HE; van den Bemt BJF; van Puijenbroek EP; Jessurun NT
    Drug Saf; 2023 Oct; 46(10):1039-1047. PubMed ID: 37651084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.